Hematology in COVID-19 patients
The study of blood-related difficulties in COVID-19 individuals who have the SARS-CoV-2 virus infection is referred to as haematology. It has been discovered that COVID-19 has a variety of effects on the blood system, including irregular blood coagulation, anaemia, and low platelet counts.
In severe COVID-19 patients, abnormal blood clotting is a frequent consequence that can result in life-threatening conditions including stroke and pulmonary embolism. These patients' care may involve haematologists, who may prescribe anticoagulant medications to stop blood clotting.
COVID-19 can also cause anemia, a condition in which there is a deficiency of red blood cells, which can lead to fatigue, weakness, and shortness of breath. Hematologists may perform blood transfusions or prescribe medications to treat anemia in COVID-19 patients.
Low platelet counts, a condition known as thrombocytopenia, have also been reported in some COVID-19 patients. This can lead to an increased risk of bleeding and may require platelet transfusions or other treatments.
- Hematologic Manifestations of COVID-19
- Coagulopathy in COVID-19 Patients
- COVID-19 and Hematopoietic Stem Cell Transplantation
- Impact of COVID-19 on the Diagnosis and Management of Hematologic Malignancies
Related Conference of Hematology in COVID-19 patients
Hematology in COVID-19 patients Conference Speakers
Recommended Sessions
- Anemia
- Biomarkers in Hematology
- Bleeding Disorders
- Clinical and Experimental Hematology
- Coagulopathies
- Gene and Cell Therapies for Blood Disorders
- Hematologic Malignancies
- Hematology and neurological disorders
- Hematology in COVID-19 patients
- Hematology in Pediatrics
- Hematology-oncology
- Hematopoietic Stem Cell Transplantation
- Hemostasis
- HIV/AIDS
- Immunohematology
- Immunotherapy for Blood Disorders
- Leukemia
- Myeloma
- Rare Blood Disorders
- Thalassemia
- Thrombosis and Hemostasis
Related Journals
Are you interested in
- Bleeding Disorders in Women - Blood Disorders 2024 (Ireland)
- Digital Health and Artificial Intelligence (AI) in Hematology - Blood Disorders 2024 (Ireland)
- Hematologic Gene Editing and Gene Therapies - Blood Disorders 2024 (Ireland)
- Hematology and Stem Cell Research - Blood Disorders 2024 (Ireland)
- Hematopoietic Stem Cell Transplantation - Blood Disorders 2024 (Ireland)
- Hemoglobinopathies and Sickle Cell Disease - Blood Disorders 2024 (Ireland)
- Hemophilia Management and Research - Blood Disorders 2024 (Ireland)
- Hemostasis and Thrombosis - Blood Disorders 2024 (Ireland)
- Immunotherapy and Hematology - Blood Disorders 2024 (Ireland)
- Leukemia and Lymphoma - Blood Disorders 2024 (Ireland)
- Medicine in Hematology - Blood Disorders 2024 (Ireland)
- Molecular Hematology - Blood Disorders 2024 (Ireland)
- Myelodysplastic Syndromes (MDS) and Bone Marrow Failure - Blood Disorders 2024 (Ireland)
- Next-Generation Diagnostics and Imaging - Blood Disorders 2024 (Ireland)
- Novel Therapies for Blood Cancers - Blood Disorders 2024 (Ireland)
- Pediatric Hematology - Blood Disorders 2024 (Ireland)
- Platelet Disorders - Blood Disorders 2024 (Ireland)
- Sickle Cell Disease (SCD) - Blood Disorders 2024 (Ireland)
- Thalassemia Management - Blood Disorders 2024 (Ireland)
- Transfusion Medicine and Blood Banking - Blood Disorders 2024 (Ireland)